logo
Plus   Neg
Share
Email

Roche & Atea Join To Develop AT-527 As Treatment For COVID-19 Patients

Roche (RHHBY) and Atea Pharmaceuticals, Inc. have agreed to collaborate to develop, manufacture and distribute AT-527, Atea's investigational oral direct-acting antiviral, as a potential oral treatment for COVID-19 patients. If approved, Atea will distribute AT-527 in the United States and Roche will be responsible for global manufacturing and distribution outside the United States.

AT-527 is an investigational, oral, purine nucleotide prodrug, which has demonstrated in vitro and in vivo antiviral activity against several enveloped single-stranded RNA viruses, including human flaviviruses and coronaviruses.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After providing free and discounted rides to the polls on Election Day, Lyft is now set to support voters with discounted rides to the polls for the federal runoff races in Louisiana and Georgia. They also provided similar rides during the primary season. The ride-sharing company is continuing its Voting Access Program to provide affordable transportation to voters in need. Discount retailer Dollar General Corp. and supermarket chain Kroger Co. on Thursday reported sharp increases in their quarterly profits on higher sales. While Dollar General's results trounced analysts' estimates, Kroger's earnings beat expectations while revenue fell short. Dollar General's profit for the third quarter surged 57 percent from last year. On January 4, 2021, Discovery plans to launch its new standalone streaming service called Discovery+ which will also offer exclusive streaming access to the BBC's award-winning natural history shows like Planet Earth, Blue Planet, and Frozen Planet. The channel is expected to offer the largest content of real-life entertainment provided by any streaming platform at launch.
Follow RTT